Efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses

doi:10.19438/j.cjoms.2017.02.010

Abstract

Abstract: PURPOSE : To estimate the efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses. METHODS : From March, 2013 to March, 2015, 29 infantile hemangiomas in the noses were treated with oral propranolol at a dose of 2.0 mg/(kg·d), divided into 2 times. The changes of the tumor size, texture and color were monitored and recorded at a regular interval. The adverse reactions after medication were observed and managed accordingly. The efficacy was evaluated using Achauer's system. RESULTS : The average mediation duration was 6 months. The overall response was gradeⅡ in 2 patients, grade Ⅲ in 9 patients, grade Ⅳ in 18 patients. Adverse reactions were observed in 2 patients, including mild diarrhea and sleep disturbance. CONCLUSION S: Oral propranolol is effective and safe for the treatment of infantile hemangiomas in the noses, and the adverse reaction is minimal.

Key words: Hemangioma, Propranolol, Infant

CLC Number:

R732.2

ZHAO Zhi-guo, PAN Yao, YANG Dong-sheng, ZHANG Li-ping. Efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses[J]. China Journal of Oral and Maxillofacial Surgery, 2017, 15(2): 147-152.

References

[1] Shah S, Frieden IJ. Treatment of infantile hemangiomas with Beta-blockers: a review [J].Skin Therapy Lett, 2013, 18(6): 5-7.
[2] 郑家伟. 婴幼儿血管瘤“等待观察”的治疗策略应予改变 [J].中国口腔颌面外科杂志, 2012, 10(2): 163-164.
[3] 张继斌, 刘军, 陈松龄. 婴幼儿腮腺血管瘤的治疗探讨 [J].口腔医学, 2014, 34(7): 555-557.
[4] Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas[J]. Arch Otolaryngol Head Neck Surg, 2011, 137(5): 471-478.
[5] Bruckner AL, Frienden IJ. Hemangiomas of infancy[J]. J Am Acad Dermatol, 2003, 48(4): 477-493.
[6] Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients [J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[7] Chang LC, Haggstrom AN, Drolet BA, et al. Growth characterisities of infantile hemangiomas: implications for management [J].Pediatrics, 2008, 122(2): 360-367.
[8] 王绪凯.脉管性疾病的治疗 [J].中国实用口腔科杂志, 2009, 2(5): 280-282.
[9] Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of literature [J]. Int J Pediatr Otorhinolaryngol, 2010, 74(4): 338-342.
[10] Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action [J]. Br J Dermatol, 2010, 163(2): 269-274.
[11] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J].N Engl J Med, 2008, 358(24): 2649-2651.
[12] Hogeling M, Adams S, Wargon O. A randomized controlled trial of opranolol for infantile hemangiomas [J]. Pediatrics, 2011, 128(2): e259-266.
[13] Hermans DJ, Bauland CG, Zweegers J, et al. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions [J].Br J Dermatol, 2013, 168(4): 837-843.
[14] Pope E, Chakkittakandiyil A, Lara-Corrales I, et al. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol [J]. Br J Dermatol, 2013, 168(1): 222-224.
[15] Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference [J]. Pediatrics, 2013, 131(1): 128-140.
[16] 郑家伟, 张凌, 陈正岗. 普萘洛尔治疗婴幼儿血管瘤专家共识[J]. 中国口腔颌面外科杂志, 2013, 11(2): 161-164.